Search, analyze & compare

My selected companies

Adjust valuation method
WatchlistNameTickerP/EP/SP/BEV/EbitdaROEROICRSISMA200DCFVolumeClosing price
-
CalAmp CorpCAMP-0.932.12-0.72-3.2839.84%-54.22%43.17$97.11$89.311,179$5.86

Detail of CalAmp Corp

 
CEO
Mr. Joshua Mandel-Brehm
Employees
58
Industry
Biotechnology
Sector
Healthcare
Market cap
$114M

Company details

Camp4 Therapeutics Corporation, a clinical-stage biopharmaceutical company, discovers and develops regulatory RNA-based therapeutics to treat a range of genetic diseases. Its lead product candidate is CMP-CPS-001 for the treatment of urea cycle disorders. The company also develops CMP-SYNGAP to treat synaptic Ras GTPase activating protein 1-related disorders. Camp4 Therapeutics Corporation was formerly known as Marauder Therapeutics, Inc. and changed its name to Camp4 Therapeutics Corporation in March 2018. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.

Revenue
Cost of goods
Gross profit
OE
R&D
G&A
OI
OIE
PI
TAX
NI
Revenue (Rev)
$53.98M
Cost of goods (CoG)
-$36.05M
Gross profit (GP)
$17.57M
Operating expense (OE)
-$62.73M
Research and development (R&D)
-$34.23M
General and administrative (G&A)
-$28.50M
Operating income (OI)
-$45.92M
Other income expense (OIE)
-$77.16M
Pretax income (PI)
-$123.14M
Tax (TAX)
-$38,000.00
Net income (NI)
-$123.17M
CalAmp Corp
CAMP • XNGS • US
$5.86
+5.58 (2,415.15%)
Stock vs Industry average
  • Industry average

Negative values are hidden from the graph.
Dividend yield
341.30%
Trailing annual dividend rate
$0.00
Payout ratio
0.00%
EPS
-$6.31
Margin profit
0.00%
52 week low
$0.03
52 week high
$390.00
50-day simple moving average
$7.41
200-day simple moving average
$97.11
Percent held by insiders
36.59%
Percent held by institutions
42.04%
Dividend yield
0.00%

Change of shares

Cash vs Debt

Insider Trading

Comparison of selected companies

 
%
Price change
CAMP +2,252.23%
eps change
CAMP 0.00%